{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:07:19Z","timestamp":1779268039659,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04900-1","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:20:34Z","timestamp":1779265234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically based pharmacokinetic modeling of granisetron for optimizing antiemetic therapy in patients with cancer: multi-route pharmacokinetic characterization and target-site exposure prediction"],"prefix":"10.1007","volume":"96","author":[{"given":"Ji-Hun","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"4900_CR1","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","volume":"26","author":"K Gupta","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP (2021) Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. Cancer Treat Res Commun 26:100278. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100278","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"4900_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jradnu.2023.04.002","volume":"42","author":"S Gautam","year":"2023","unstructured":"Gautam S, Sharma KK, Amanat M (2023) Management of Chemotherapy Induced Nausea Vomiting (CINV) in Breast Cancer Patients: An Imperative Factor in Patient Compliance. J Radiol Nurs 42(3):315\u2013320. https:\/\/doi.org\/10.1016\/j.jradnu.2023.04.002","journal-title":"J Radiol Nurs"},{"issue":"6","key":"4900_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdv138","volume":"26","author":"K Jordan","year":"2015","unstructured":"Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26(6):1081\u20131090. https:\/\/doi.org\/10.1093\/annonc\/mdv138","journal-title":"Ann Oncol"},{"issue":"18","key":"4900_CR4","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s40265-016-0663-3","volume":"76","author":"AL Kovac","year":"2016","unstructured":"Kovac AL (2016) Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting. Drugs 76(18):1719\u20131735. https:\/\/doi.org\/10.1007\/s40265-016-0663-3","journal-title":"Drugs"},{"key":"4900_CR5","doi-asserted-by":"publisher","unstructured":"Kitayama H (2016) Granisetron Transdermal System in the Management of Chemotherapy-Induced Nausea and Vomiting. Clin Med Insights Ther 8. https:\/\/doi.org\/10.4137\/CMT.S10240","DOI":"10.4137\/CMT.S10240"},{"issue":"12","key":"4900_CR6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1080\/17425255.2017.1396317","volume":"13","author":"A Spartinou","year":"2017","unstructured":"Spartinou A, Nyktari V, Papaioannou A (2017) Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced - nausea and vomiting. Expert Opin Drug Metab Toxicol 13(12):1289\u20131297. https:\/\/doi.org\/10.1080\/17425255.2017.1396317","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"4900_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/14656566.2017.1342809","volume":"18","author":"SA Doggrell","year":"2017","unstructured":"Doggrell SA (2017) Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) \u2013 is there still a role after comparison with palonosetron? Expert Opin Pharmacother 18(10):1019\u20131026. https:\/\/doi.org\/10.1080\/14656566.2017.1342809","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"4900_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1634\/theoncologist.9-6-673","volume":"9","author":"M Aapro","year":"2004","unstructured":"Aapro M (2004) Granisetron: An Update on its Clinical Use in the Management of Nausea and Vomiting. Oncologist 9(6):673\u2013686. https:\/\/doi.org\/10.1634\/theoncologist.9-6-673","journal-title":"Oncologist"},{"issue":"4","key":"4900_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1078155209104063","volume":"15","author":"J Howell","year":"2009","unstructured":"Howell J, Smeets J, Drenth H-J, Gill D (2009) Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract 15(4):223\u2013231. https:\/\/doi.org\/10.1177\/1078155209104063","journal-title":"J Oncol Pharm Pract"},{"key":"4900_CR10","doi-asserted-by":"publisher","unstructured":"Haislip ST, Gilmore JW, Howell JD (2013) Results from four pharmacokinetic studies of the granisetron transdermal system. Res Rep Transdermal Drug Deliv 2 (null):19\u201326. https:\/\/doi.org\/10.2147\/RRTD.S42934","DOI":"10.2147\/RRTD.S42934"},{"issue":"1","key":"4900_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5414\/CP203327","volume":"57","author":"R Chen","year":"2019","unstructured":"Chen R, Chen X, Wang H, Zhong W, Oh ES, Park MS, Kumagai Y, Zhou L, Nagahama F, Hu P (2019) Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects: An open-label, randomized, crossover study. Int J Clin Pharmacol Ther 57(1):24","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4900_CR12","doi-asserted-by":"publisher","first-page":"1154026","DOI":"10.3389\/fphar.2023.1154026","volume":"14","author":"J Li","year":"2023","unstructured":"Li J, Hu P, Zhou L, Nagahama F, Chen R (2023) Population pharmacokinetic analysis of transdermal granisetron in healthy Chinese and Caucasian volunteers. Front Pharmacol 14:1154026. https:\/\/doi.org\/10.3389\/fphar.2023.1154026","journal-title":"Front Pharmacol"},{"issue":"1","key":"4900_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/BF00254104","volume":"24","author":"J Carmichael","year":"1989","unstructured":"Carmichael J, Cantwell BMJ, Edwards CM, Zussman BD, Thompson S, Rapeport WG, Harris AL (1989) A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 24(1):45\u201349. https:\/\/doi.org\/10.1007\/BF00254104","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4900_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1248\/bpb.24.432","volume":"24","author":"I Wada","year":"2001","unstructured":"Wada I, Takeda T, Sato M, SAITOH H, NAKABAYASHI T, MINO K, HONMA T, TAKADA M, HIRANO K (2001) Pharmacokinetics of granisetron in adults and children with malignant diseases. Biol Pharm Bull 24(4):432\u2013435. https:\/\/doi.org\/10.1248\/bpb.24.432","journal-title":"Biol Pharm Bull"},{"issue":"9","key":"4900_CR15","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1634\/theoncologist.12-9-1151","volume":"12","author":"A Gurpide","year":"2007","unstructured":"Gurpide A, Sadaba B, Martin-Algarra S, Azanza JR, Lopez-Picazo JM, Campanero MA, Cabello JP, Gil-Aldea I, de la Cruz S, Gallego VF, Reyna C, Garate CO, Blanco-Prieto MJ, Ceballos J, Garcia-Foncillas J, Perez-Gracia JL (2007) Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated with Platinum-Based Chemotherapy. Oncologist 12(9):1151\u20131155. https:\/\/doi.org\/10.1634\/theoncologist.12-9-1151","journal-title":"Oncologist"},{"issue":"null","key":"4900_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/CMAR.S72626","volume":"7","author":"N Gabrail","year":"2015","unstructured":"Gabrail N, Yanagihara R, Spaczy\u0144ski M, Cooper W, O\u2019Boyle E, Smith C, Boccia R (2015) Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials. Cancer Manag Res 7(null):83\u201392. https:\/\/doi.org\/10.2147\/CMAR.S72626","journal-title":"Cancer Manag Res"},{"issue":"12","key":"4900_CR17","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/bmc.3233","volume":"28","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Jiang J, Hu P, Wang H (2014) A high-performance liquid chromatography\u2013tandem mass spectrometry method coupled with protein precipitation for determination of granisetron in human plasma and its application to a comparative pharmacokinetic study. Biomed Chromatogr 28(12):1597\u20131600. https:\/\/doi.org\/10.1002\/bmc.3233","journal-title":"Biomed Chromatogr"},{"issue":"9","key":"4900_CR18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/bmc.613","volume":"20","author":"RVS Nirogi","year":"2006","unstructured":"Nirogi RVS, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R (2006) Quantification of granisetron in human plasma by liquid chromatography coupled to electrospray tandem mass spectrometry. Biomed Chromatogr 20(9):888\u2013897. https:\/\/doi.org\/10.1002\/bmc.613","journal-title":"Biomed Chromatogr"},{"issue":"5","key":"4900_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0149-2918(03)80128-5","volume":"25","author":"RA Blum","year":"2003","unstructured":"Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE (2003) Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 25(5):1407\u20131419. https:\/\/doi.org\/10.1016\/S0149-2918(03)80128-5","journal-title":"Clin Ther"},{"issue":"12","key":"4900_CR20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/jps.2600821221","volume":"82","author":"D Cupissol","year":"1993","unstructured":"Cupissol D, Bressolle F, Adenis L, Carmichael J, Bessell E, Allen A, Wargenau M, Romain D (1993) Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease. J Pharm Sci 82(12):1281\u20131284. https:\/\/doi.org\/10.1002\/jps.2600821221","journal-title":"J Pharm Sci"},{"issue":"4","key":"4900_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jpba.2006.05.001","volume":"42","author":"Y Jiang","year":"2006","unstructured":"Jiang Y, Lin M, Fan G, Chen Y, Li Z, Zhao W, Wu Y, Hu J (2006) Rapid determination of granisetron in human plasma by liquid chromatography coupled to tandem mass spectrometry and its application to bioequivalence study. J Pharm Biomed Anal 42(4):464\u2013473. https:\/\/doi.org\/10.1016\/j.jpba.2006.05.001","journal-title":"J Pharm Biomed Anal"},{"key":"4900_CR22","doi-asserted-by":"publisher","unstructured":"Jiang L, Mao L, Lin J, Cheng J, Liu Z, Zhao H, Zhang X, Wang C, Deng L (2024) Pharmacokinetic study of granisetron in human plasma measured by UPLC-MS\/MS and its use in healthy Chinese subjects. Pak J Pharm Sci 37(3). https:\/\/doi.org\/10.36721\/PJPS.2024.37.3.REG.475-489.1","DOI":"10.36721\/PJPS.2024.37.3.REG.475-489.1"},{"key":"4900_CR23","unstructured":"DrugBank, Granisetron https:\/\/go.drugbank.com\/drugs\/DB00889 , Accessed on Nov. 03.2025."},{"issue":"6","key":"4900_CR24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1021\/acs.chemrestox.8b00413","volume":"32","author":"D Lang","year":"2019","unstructured":"Lang D, Radtke M, Bairlein M (2019) Highly variable expression of CYP1A1 in human liver and impact on pharmacokinetics of riociguat and granisetron in humans. Chem Res Toxicol 32(6):1115\u20131122. https:\/\/doi.org\/10.1021\/acs.chemrestox.8b00413","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"4900_CR25","doi-asserted-by":"publisher","first-page":"100064","DOI":"10.1016\/j.dmd.2025.100064","volume":"53","author":"A-K Lenich","year":"2025","unstructured":"Lenich A-K, Nilles J, Scherer V, Li F, Ruez S (2025) Assessing granisetron as a specific CYP1A1 substrate in primary human hepatocytes: A comprehensive evaluation for drug development studies. Drug Metab Dispos 53(4):100064. https:\/\/doi.org\/10.1016\/j.dmd.2025.100064","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"4900_CR26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2174\/138920005774330666","volume":"6","author":"H Nakamura","year":"2005","unstructured":"Nakamura H, Ariyoshi N, Okada K, Nakasa H, Nakazawa K, Kitada M (2005) CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab 6(5):469\u2013480. https:\/\/doi.org\/10.2174\/138920005774330666","journal-title":"Curr Drug Metab"},{"issue":"6","key":"4900_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1365-2125.1994.tb04397.x","volume":"38","author":"J Bloomer","year":"1994","unstructured":"Bloomer J, Baldwin S, Smith G, Ayrton A, Clarke S, Chenery R (1994) Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 38(6):557\u2013566. https:\/\/doi.org\/10.1111\/j.1365-2125.1994.tb04397.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4900_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cpt.1013","volume":"104","author":"M Shebley","year":"2018","unstructured":"Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, Peters SA, Reddy VP, Zheng M, de Zwart L, Beneton M, Bouzom F, Chen J, Chen Y, Cleary Y, Collins C, Dickinson GL, Djebli N, Einolf HJ, Gardner I, Huth F, Kazmi F, Khalil F, Lin J, Odinecs A, Patel C, Rong H, Schuck E, Sharma P, Wu S-P, Xu Y, Yamazaki S, Yoshida K, Rowland M (2018) Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective. Clin Pharmacol Ther 104(1):88\u2013110. https:\/\/doi.org\/10.1002\/cpt.1013","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4900_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1208\/s12248-025-01155-1","volume":"27","author":"MA Tegenge","year":"2025","unstructured":"Tegenge MA, Yogurtcu ON, Belov AA, Wang X, Forshee RA (2025) Physiologically Based Pharmacokinetic Modeling and Simulation in Regulatory Review: US FDA CBER Experience and Perspectives. AAPS J 27(6):157. https:\/\/doi.org\/10.1208\/s12248-025-01155-1","journal-title":"AAPS J"},{"issue":"11","key":"4900_CR30","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/pharmaceutics17111413","volume":"17","author":"Y Li","year":"2025","unstructured":"Li Y, Sun H, Zhang Z (2025) The Evolution and Future Directions of PBPK Modeling in FDA Regulatory Review. Pharmaceutics 17(11):1413. https:\/\/doi.org\/10.3390\/pharmaceutics17111413","journal-title":"Pharmaceutics"},{"issue":"5","key":"4900_CR31","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2165\/00003495-199142050-00007","volume":"42","author":"GL Plosker","year":"1991","unstructured":"Plosker GL, Goa KL (1991) Granisetron Drugs 42(5):805\u2013824. https:\/\/doi.org\/10.2165\/00003495-199142050-00007","journal-title":"Granisetron Drugs"},{"issue":"3","key":"4900_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13318-025-00938-3","volume":"50","author":"J-H Jang","year":"2025","unstructured":"Jang J-H, Jeong S-H (2025) Development of a Physiologically-Based Pharmacokinetic Model for Quantitative Interpretation of Transdermal Drug Delivery of Rotigotine, a Dopamine Agonist for Treating Parkinson\u2019s Disease. Eur J Drug Metab Pharmacokinet 50(3):187\u2013204. https:\/\/doi.org\/10.1007\/s13318-025-00938-3","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"4900_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1208\/s12249-024-02995-4","volume":"26","author":"J-H Jang","year":"2024","unstructured":"Jang J-H, Jeong S-H (2024) Pharmacokinetic Prediction of Immediate- and Extended-Release Tablets for Patients with Liver Disease Using Whole Body Physiologically-Based Pharmacokinetic Modeling for the Antipsychotic Drug Quetiapine. AAPS PharmSciTech 26(1):8. https:\/\/doi.org\/10.1208\/s12249-024-02995-4","journal-title":"AAPS PharmSciTech"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04900-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04900-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04900-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:20:36Z","timestamp":1779265236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04900-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4900"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04900-1","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}